CD40LG and diffuse large B-cell lymphoma: The study also revealed potent activity of KPT-335 in one cell line each for canine diffuse large B-cell lymphoma (DLBCL), mast cell tumor, melanoma, and osteosarcoma, as well as clinical samples of canine DLBCL cultured with CD40L stimulation.